Valve: Music video with GlaDOS is supposed to teach Gabe Newell to count
Valve
For many years, Valve fans have made a little fun of the fact that the company seems to have forgotten how counting works. Valve recently released a new offshoot of the series with Half-Life: Alyx, but titles such as Half-Life 2, Portal 2 or Left 4 Dead 2 are still waiting for a real successor. In a current music video, exactly this topic is now taken up. Including guest appearances by GLaDOS and Gabe Newell personally.The group from The Chalkeaters is responsible for the song "Count to Three". Both the video and the text are packed with small details and inside gags from the Valve universe. While the main part of the song is being sung by The Stupendium from London, Gabe Newell actually did a sound recording especially for the music video. In addition, fans can look forward to Ellen McLain, who has returned to the role of GLaDOS.
Recommended editorial content Here you will find external content from [PLATTFORM]. To protect your personal data, external integrations are only displayed if you confirm this by clicking on "Load all external content": Load all external content I consent to external content being displayed to me. This means that personal data is transmitted to third-party platforms. Read more about our privacy policy . External content More on this in our data protection declaration. Count to Three can now also be found on Spotify, Apple Music and Amazon Music. Just last week Valve commented more or less on Half-Life 3. So the studio would like to continue working on new games in the half-life universe. In the interview, however, the person in charge did not want to reveal whether this is specifically part 3.
Recommended editorial content At this point you will find external content from [PLATTFORM]. To protect your personal data, external integrations are only displayed if you confirm this by clicking on "Load all external content": Load all external content I consent to external content being displayed to me. This means that personal data is transmitted to third-party platforms. Read more about our privacy policy . External content More on this in our data protection declaration. Half-Life: Alyx was released almost a year ago exclusively for VR devices. In the test, we took a closer look at the return of the Shooter series. For the anniversary, Valve is currently offering the title 40% cheaper on Steam for 29.99 euros instead of 49.99 euros.
FDA approves first nonsurgical heart valve for congenital heart disease
(HealthDay)—The first-ever nonsurgical heart valve to treat patients with severe pulmonary valve regurgitation, often resulting from congenital heart disease, was approved by the U.S. Food and Drug Administration, the agency announced Friday.
The Harmony Transcatheter Pulmonary Valve System, intended for patients with a native or surgically repaired right ventricular outflow tract (RVOT), improves blood flow to the lungs without the use of open-heart surgery. Use of the Harmony system may allow patients to delay the time before they need to undergo open-heart surgery and can reduce the total number of open-heart surgeries a patient needs in their lifetime, the FDA notes.
During implantation of the device, the surgeon inserts a catheter with a collapsed Harmony valve on the insertion end through a vein in the groin or neck and into the right side of the heart and then into the RVOT. The valve is then placed into position and released from the catheter. It expands on its own and anchors to the RVOT. Once in place, the valve opens and closes to force blood to flow in the correct direction.
The approval of the Harmony device was based on data from the Harmony TPV clinical study, a prospective, nonrandomized, multicenter study in 70 patients who underwent the implant procedure and were followed up at one month, six months, and annually through five years. The FDA notes follow-up has now been extended to 10 years for the postapproval study. For patients with available echocardiography data, 89.2 percent underwent no additional surgery or interventional procedures related to the device and had acceptable heart blood flow function at six months. All patients achieved the primary safety end point of no deaths related to the procedure or device within 30 days following implantation.
The most commonly reported adverse events were irregular or abnormal heart rhythms, leakage around the valve, minor bleeding, narrowing of the pulmonary valve, and movement of the implant.
Approval was granted to Medtronic.
More information: More InformationCopyright © 2021 HealthDay. All rights reserved.
Citation: FDA approves first nonsurgical heart valve for congenital heart disease (2021, March 30) retrieved 30 March 2021 from https://medicalxpress.com/news/2021-03-fda-nonsurgical-heart-valve-congenital.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
